BostonGene Highlights Innovative Cancer Research at SITC
BostonGene, recognized for its cutting-edge AI-driven molecular and immune profiling solutions, is gearing up to participate in a significant event—the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting. This prominent event is scheduled to run from November 6 to November 10 at the George R. Brown Convention Center. BostonGene will present six compelling research posters developed in collaboration with leading cancer research centers.
Research Presentation Details
Among the numerous contributions at this meeting, BostonGene's research aims to illustrate the profound impact of its technology on cancer treatment strategies. The studies range from deep molecular insights to predictive biomarkers that facilitate personalized treatment plans. As part of their presence, the company will also have a booth (514) where attendees can explore more about their innovative approaches.
Featured Abstracts from BostonGene
Below are some exciting presentations that BostonGene will showcase:
Exploring Tumor Microenvironments
Abstract number: 135
Title: Multiplex immunofluorescence of whole slide images for enhanced tumor microenvironment immune cell characterization in multiple cancer types
Date & Time: Friday, November 8 | 9:00 AM to 7:00 PM CST
Presenter: Vladimir Kushnarev, MD, PhD, BostonGene
This study illustrates the use of BostonGene’s advanced multiplex immunofluorescence (MxIF) pipeline to analyze immune cell types present in the tumor microenvironment. The findings emphasize the varied nature of tumor microenvironments across different cancer types, highlighting the need for personalized immunotherapeutic strategies.
Genomic Profiling Insights
Abstract number: 161
Title: The predictive role of comprehensive genomic profiling in angiosarcoma immunotherapy
Date & Time: Friday, November 8 | 9:00 AM to 7:00 PM CST
Presenter: Nikita Kotlov, BostonGene
This research delves into the comprehensive genomic profiling of angiosarcomas, a rare and aggressive cancer. Through detailed transcriptomic analysis, the study aims to identify key genetic alterations that can guide targeted therapy selection.
Understanding Sarcoma Management
Abstract number: 183
Title: Comprehensive molecular profiling in the management of patients with diverse sarcoma subtypes
Date & Time: Friday, November 8 | 9:00 AM to 7:00 PM CST
Presenter: Francesca Paradiso, PhD, BostonGene
This study outlines the findings from comprehensive molecular profiling of sarcomas, revealing a wealth of over 1,000 genetic alterations across various subtypes. The research also identifies numerous actionable findings, which could enhance strategic treatment decisions for these patients.
Machine Learning Innovations
BostonGene is also unveiling a groundbreaking study on the use of machine learning to decipher critical tumor characteristics.
Blood-Derived Data Insights
Abstract number: 46
Title: Comprehensive machine learning-driven platform infers key tumor characteristics from blood-derived cfRNA
Date & Time: Saturday, November 9 | 9:00 AM to 8:30 PM CST
Presenter: Andrey Shubin, PhD, BostonGene
The study presents a state-of-the-art machine learning platform, capable of assessing transcriptomic data derived from blood samples. This innovative approach could yield significant insights into tumor biology and aid in translating findings into clinical interventions.
Insights into Immune-Related Events
The final sessions will focus on predicting immunotherapeutic outcomes.
Identifying Adverse Events in Melanoma
Abstract number: 144
Title: Identifying a composite signature for predicting immune-related adverse events in advanced melanoma patients treated with immune checkpoint blockade
Date & Time: Saturday, November 9 | 9:00 AM to 8:30 PM CST
Presenter: Michael Goldberg, PhD, BostonGene
In this pivotal research, BostonGene aims to identify signatures that predict immune-related adverse events in melanoma patients undergoing immune checkpoint blockade therapy. By understanding the cellular and gene expression patterns, the research could pave the way for improved patient management and outcomes.
Discovering New ADC Targets
Abstract number: 170
Title: Identifying novel targets for antibody-drug conjugates in sarcomas using RNA sequencing
Date & Time: Saturday, November 9 | 9:00 AM to 8:30 PM CST
Presenter: Vladimir Kushnarev, MD, PhD, BostonGene
Using RNA sequencing, this work highlights the identification of innovative targets for antibody-drug conjugates in sarcomas, showcasing the integration of expression data with immune landscape features necessary for therapeutic strategy development.
About BostonGene Corporation
BostonGene Corporation specializes in pioneering computational biology and precision medicine. Established in 2015, the organization is dedicated to leveraging AI to unravel cancer patients’ molecular profiles, thereby enhancing treatment effectiveness. With a state-of-the-art cancer library and a CLIA-certified laboratory, BostonGene delivers clinically validated insights that propel oncology research forward.
Frequently Asked Questions
What is the focus of BostonGene's research at SITC?
BostonGene's research at SITC focuses on the advancements in cancer treatment through AI-driven molecular and immune profiling.
Where will BostonGene present their findings?
The findings will be presented at the George R. Brown Convention Center during the SITC annual meeting.
Who are the presenters from BostonGene?
Prominent researchers from BostonGene, such as Vladimir Kushnarev and Nikita Kotlov, will present various studies.
What is BostonGene's expertise in oncology?
BostonGene excels in precision medicine and computational biology, focusing on individual molecular profiles of cancer patients.
How can one learn more about BostonGene’s offerings?
To learn more, interested individuals can visit their website or contact their representatives directly for more information.
